Antibody Production Following H1N1 Influenza Vaccination After Stem Cell and Heart Transplantation

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT01008683

Enrollment

300

Registered

2009-11-06

Start date

2009-11-30

Completion date

2010-07-31

Last updated

2009-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

H1N1 Influenza

Keywords

Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccinations

Brief summary

Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. In these patients the investigators will measure the specific antibody production.

Detailed description

Stem cell and and heart transplant patients will receive pandemic H1N1 influenza vaccination according to the clinical guidelines. Two doses will be given, in 3-week interval. In these patients we will measure the specific antibody production. Blood sample 5 ml will be drawn before the first vaccine, before the second, and 3-4 weeks after the 2nd dose.

Interventions

None listed

Study design

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

No minimum to 80 Years

Healthy volunteers

Inclusion criteria

* Stem cell and and heart transplant patients who will receive pandemic H1N1 influenza vaccination according to the clinical guidelines.

Exclusion criteria

* Patients with unstable grafts.

Countries

Israel

Contacts

Primary ContactHadas Lemberg

lhadas@hadassah.org.il

Outcome results